-
-
-
-
-
-
-
Jazz Pharmaceuticals presents Modeyso data at neuro-oncology meeting
-
-
-
-
-
-
-
Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
-
-
-
-
-
-
-
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Key Update to Leadership Team
-
-
-
-
-
-
-
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
-
1,154,889 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

